CD47 and cancer: Tseng et al. also found in in vivo experiments that treatment with anti-CD47 antibodies not only allows macrophage phagocytosis of cancer cells but also promotes an anti-tumor cytotoxic T-cell immune response and reduction of FOXP3+ regulatory T-cells [23].